Tomide5 mg

Tomide is a loop diuretic that is FDA-approved (established indications) for the following uses:

• Edema associated with congestive heart failure - to reduce fluid overload.
• Edema associated with chronic renal (kidney) disease.
• Edema associated with hepatic (liver) disease/cirrhosis - typically used together with an aldosterone antagonist or potassium-sparing diuretic.
• Hypertension (high blood pressure), alone or in combination with other antihypertensive agents, to reduce the risk of fatal and non-fatal cardiovascular events.

Tomide is not approved for use in children; safety and efficacy in pediatric patients have not been established.

Each tablet of Torasemide generally contains torasemide as the active pharmaceutical ingredient, along with pharmaceutically accepted excipients such as diluents, binders, disintegrants, and lubricants. It is also available as an injectable solution for intravenous use in some markets. Strength and exact formulation vary by manufacturer and dosage form; refer to the specific product label for exact composition.

Tomide is a pyridine-sulfonylurea-derivative loop diuretic that acts primarily on the ascending limb of the loop of Henle in the kidney. It is used to manage fluid retention (edema) associated with heart failure, kidney disease, and liver disease, and to treat hypertension. Tomide has a longer duration of action than furosemide and, in some patients, more consistent oral bioavailability.

Tomide belongs to the loop diuretic class of medications (high-ceiling diuretics), structurally related to the sulfonylureas.

Torasemide inhibits the Na⁺-K⁺-2Cl⁻ (NKCC2) cotransporter in the thick ascending limb of the loop of Henle, blocking reabsorption of sodium and chloride. This increases the delivery of sodium to the distal tubule and promotes excretion of sodium, chloride, and water, producing a diuretic and natriuretic effect. Torasemide also has a mild aldosterone-antagonist-like effect on the distal tubule at higher doses, which may reduce potassium loss compared with some other loop diuretics.

Onset of diuretic action after oral administration of Torasemide is approximately 1 hour, with peak effect at 1-2 hours and a duration of action of about 6-8 hours. Oral bioavailability of Torasemide is high (approximately 80-90%) and largely unaffected by food. It is extensively metabolized in the liver (mainly via CYP2C9) and eliminated both renally and hepatically.

Tomide tablets are taken orally, once daily, with or without food, preferably in the morning. The injectable form of Tomide is given by slow intravenous injection or infusion by a healthcare professional; rapid IV administration should be avoided due to the risk of ototoxicity. Do not switch between oral and IV routes without medical guidance, as bioavailability may differ.

Tomide has the following well-established, clinically significant drug interactions:

• NSAIDs (e.g., indomethacin): May blunt the diuretic and antihypertensive effect of Tomide and increase the risk of acute kidney injury, especially in volume-depleted patients.
• ACE inhibitors / ARBs: Combined use with Tomide increases the risk of significant hypotension and renal impairment, particularly with the first dose or in volume-depleted patients.
• Aminoglycoside antibiotics or other ototoxic drugs (e.g., cisplatin): Concurrent use with Tomide increases the risk of ototoxicity and nephrotoxicity.
• Lithium: Tomide reduces renal clearance of lithium, increasing the risk of lithium toxicity; lithium levels should be monitored.
• Cholestyramine: Reduces absorption of Tomide if given together; separate dosing by at least 1 hour before or 4-6 hours after cholestyramine.
• CYP2C9 inhibitors or inducers: May alter blood levels/clearance of Tomide, changing its effect; monitoring is advised.
• Digoxin: Diuretic-induced hypokalemia can increase the risk of digoxin toxicity.
• Other antihypertensives or diuretics: Additive hypotensive and diuretic effects with Tomide are possible.

Common side effects of Tomide include increased urination, dizziness, headache, nausea, indigestion, diarrhea or constipation, joint/muscle pain, and cough.

Less common but serious side effects include electrolyte disturbances (low potassium, low sodium, low magnesium), symptomatic hypotension, ototoxicity (hearing loss, tinnitus, vertigo - especially with rapid IV administration or in patients with renal impairment), hyperglycemia (worsening glucose control in diabetics), hyperuricemia (may precipitate gout), and rarely, blood dyscrasias or severe skin reactions. Seek prompt medical attention for sudden hearing changes, severe dizziness, irregular heartbeat, or signs of severe allergic reaction.

Tomide should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; animal studies have shown fetal effects at high doses. There are no adequate, well-controlled studies in pregnant women, so a physician must be consulted before use in pregnancy.

It is not known whether Tomide passes into human breast milk. Because many diuretics can suppress lactation and some are excreted in breast milk, Tomide should be used during breastfeeding only under medical supervision, weighing the benefits against potential risks to the infant.

Tomide requires caution and monitoring in the following situations:

• Electrolyte and fluid imbalance: Tomide can cause hypokalemia, hyponatremia, hypomagnesemia, and volume depletion. Periodic monitoring of serum electrolytes, renal function, and hydration status is recommended, especially with prolonged use or high doses.
• Ototoxicity: Risk is increased with rapid intravenous administration, high doses, renal impairment, or concurrent use of other ototoxic drugs; hearing loss is usually reversible but can be permanent in rare cases.
• Renal impairment: Dose adjustment and close monitoring are needed; Tomide is contraindicated in anuria.
• Hepatic cirrhosis with ascites: Rapid diuresis can precipitate hepatic encephalopathy or hepatorenal syndrome; therapy should begin at low doses with careful monitoring (see Dosage).
• Diabetes mellitus: Tomide may worsen glucose tolerance; blood glucose should be monitored, and diabetes medication doses may need adjustment.
• Gout/hyperuricemia: Tomide may raise uric acid levels and precipitate gout attacks.
• Sulfonylurea allergy: Patients with known hypersensitivity to sulfonylureas should avoid Tomide due to possible cross-sensitivity (see Contraindications).

Tomide should be taken exactly as prescribed by a physician; do not stop, skip, or change the dose without medical advice, as abrupt discontinuation can lead to fluid retention or rebound symptoms.

Overdose of Tomide may cause excessive diuresis leading to dehydration, electrolyte depletion (particularly low potassium and sodium), hypotension, and acute kidney injury. There is no specific antidote; Tomide is not removed by dialysis. If overdose is suspected, seek immediate medical attention or contact a poison control center; treatment in a medical facility typically involves fluid and electrolyte replacement and supportive care under close monitoring.

Store Tomide at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Elderly patients are more susceptible to electrolyte disturbances, dehydration, and hypotension with Tomide; a lower starting dose and closer monitoring are advisable.

Renal impairment: Tomide is contraindicated in anuric patients; dose adjustment and monitoring are needed in other degrees of renal impairment.

Hepatic impairment: Lower starting doses are used in hepatic cirrhosis with careful monitoring to avoid encephalopathy (see Precautions).

Pediatric patients: Safety and efficacy of Tomide have not been established in children; its use is not recommended in this population.

Diabetic patients: Tomide may affect glucose tolerance; blood glucose should be monitored.

Duration of treatment with Tomide depends on the underlying condition and clinical response. Edema and hypertension often require long-term or chronic therapy, with periodic reassessment of dose, renal function, and electrolytes by the prescribing physician. Do not stop Tomide abruptly without medical advice.

Torasemide is classified as a loop diuretic (high-ceiling diuretic), within the broader category of diuretics/antihypertensive agents.

Torasemide works by inhibiting the Na⁺-K⁺-2Cl⁻ cotransporter in the thick ascending limb of the loop of Henle, which blocks sodium and chloride reabsorption. This increases urinary excretion of sodium, chloride, and water, reducing fluid volume and blood pressure.

The safety and efficacy of Tomide have not been established in pediatric patients (under 18 years of age). It is therefore not recommended for use in children, and no pediatric dosing regimen is established. Use in children should only occur under specialist medical supervision if no suitable alternative exists.